A PROSPECTIVE OBSERVATIONAL STUDY ON DISTRIBUTION PATTERN OF ADVERSE EFFECTS OF BRONCHODILATORS AMONG BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL IN A RURAL AREA OF KANCHEEPURAM DISTRICT
Objectives: The objectives of the study were (i) to study the distribution pattern of adverse effects of bronchodilators at initiation or during the course of therapy, (ii) to make a causality assessment of adverse effect identified using the WHO adverse drug reaction (ADR) probability scale, and (iii) to identify next drug tolerated better by him/her.
Materials and Methods: This is an observational study that lasted for duration of 2 months.
Inclusion Criteria: All patients reporting ADR after initiation of bronchodilator or during the course of bronchodilator therapy for bronchial asthma/ chronic obstructive pulmonary disease within the study period were included in the study. The suspected adverse effect was noted and documented. Causality assessment based on the WHO scale was employed.
Results: During the study period, ten patients reported to have ADR for bronchodilators were identified and the WHO Causality Scale for ADR was applied and the better drug tolerated by the patient was noted.
Conclusion: Inhalational forms of longer acting beta-2 agonists were better compliable to the patients with no observable adverse effects.
2. Available from: https//www.researchgate.net publications.
3. Morley J. Beta agonists and asthma mortality: Déjà vu. Clin Exp Allergy 1992;22:724-5.
4. Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P, Rossi S, et al. Effect of inhaled glucocorticoids and ?2 agonists on vertebral fracture risk in COPD patients: The EOLO study. Calcif Tissue Int 2010;87:137-43.
5. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001;87:379-85.
6. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12:201-9.
7. Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 1992;227:403-9.
8. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.